Explore the Global Self-Amplifying RNA Cancer Immunotherapy Platforms Market— analysis of key trends, regional growth, top players, and a 10-year forecast from 2026 to 2036.

Future Market Insights

Self-Amplifying RNA Cancer Immunotherapy Platforms Market

Key Insight

FMI opines the self-amplifying RNA cancer immunotherapy platforms market was valued at USD 94.0 million in 2025. The industry is expected to cross USD 112.0 million in 2026 and USD 643.2 million by 2036. Personalized neoantigen saRNA platforms is poised to lead by Platform type with 42.6% share in 2026, and Lipid nanoparticle (LNP)-based delivery is estimated to dominate by Delivery system through 2036.

March 16, 2026

Anurag Sharma

250 Pages

Cite this Report

Self-Amplifying RNA Cancer Immunotherapy Platforms Market

https://www.futuremarketinsights.com/reports/self-amplifying-rna-cancer-immunotherapy-platforms-market

License

Starting at US$ 5000

Buy Now

Summary ToC Infographics Companies

Key Players

AlphaVax
Arcturus Therapeutics Holdings Inc
BioNTech SE
HDT Bio Corp
Immorna Biotherapeutics
Immunomic Therapeutics
Meiji Seika Pharma

Methodology

Member of

Greater New York Chamber of Commerce

Recognized by

Awarded by

SILVER STEVIE® WINNER

Asia Pacific Stevie Awards - 2023

BRONZE STEVIE® Award

20th annual IBAs

Quick Contact

Chat on Whatsapp + 44 20 3769 9709 + 1 347 918 3531 Contact By Email

Get Free Sample PDF

Self-Amplifying RNA Cancer Immunotherapy Platforms Market

Key Players

Similar Industry Reports